Hinge Health Q2 revenue rises 53% to $212.8 million; raises 2026 revenue guidance
Hinge Health reported second-quarter 2026 revenue of $212.8 million, up 53% from a year earlier, and GAAP diluted earnings of $0.52 per share, compared with a loss of $13.10 per share in the second quarter of 2025. The company raised its full-year 2026 revenue guidance to $856 million to $860 million, agreed to buy Cylinder Health for $105 million in cash, and its board increased the share repurchase program by $300.0 million, for a total authorization of $496.5 million.
Key points
- Q2 2026 revenue was $212.8 million, up 53% from $139.1 million in Q2 2025; GAAP income from operations was $40.4 million, compared with a loss of $580.7 million a year earlier
- Full-year 2026 revenue guidance raised to $856 million to $860 million; Q3 2026 revenue guidance set at $223 million to $225 million
- Definitive agreement to acquire Cylinder Health, Inc. for $105 million in cash, expected to close in the third quarter of 2026
- As of July 29, 2026, $196.5 million of stock had been repurchased under the program; the board approved a $300.0 million increase, bringing total authorization to $496.5 million
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.